Oral liquids

Procedures and tools

• SOP-009Oral solutions, syrups and suspensions
• SOP-023Clinical excipient and dose review
• SOP-027Suitability for an enteral feeding tube
• F-021Clinical excipient exposure and device/route suitability
• PUB-016Clinical excipient assessment and daily exposure
• PUB-017Analytical testing and actual delivered dose

Related monographs

73 records in the collection

• CGR-BP-022

  Syrup

  Reference monograph · Local adoption

• CGR-BP-031

  Aqueous Iodine Oral Solution

  Reference monograph · Local adoption

• CGR-BE-015

  Omeprazole oral suspension 2 mg/g FTM

  Reference monograph · Local adoption

• CGR-BE-017

  Macrocrystalline nitrofurantoin oral suspension 6 mg/mL FTM

  Reference monograph · Local adoption

• CGR-BE-018

  Trimethoprim oral suspension 10 mg/mL FTM

  Reference monograph · Local adoption

• CGR-BE-020

  Miconazole base oral gel 2% FTM

  Reference monograph · Local adoption

• CGR-FR-021

  Acacia oral vehicle (potion gommeuse) Ph. Fr.

  Reference monograph · Local adoption

• CGR-FR-026

  Therapeutic placebo syrup Ph. Fr.

  Reference monograph · Local adoption

• CGR-FR-027

  Simple syrup Ph. Fr.

  Reference monograph · Local adoption

• CGR-FR-028

  Glycerol oral solution 0.644 g/mL Ph. Fr.

  Reference monograph · Local adoption

• CGR-ES-003

  AEMPS preserved syrup — nominal 84% w/v

  Reference monograph · Local adoption

• CGR-ES-004

  Sodium carmellose oral gel 1% AEMPS

  Reference monograph · Local adoption

• CGR-ES-006

  Hydrochlorothiazide oral suspension 2 mg/mL AEMPS

  Reference monograph · Local adoption

• CGR-ES-007

  Captopril oral solution 1 mg/mL AEMPS

  Reference monograph · Local adoption

• CGR-ES-008

  Furosemide oral solution 2 mg/mL AEMPS

  Reference monograph · Local adoption

• CGR-ES-009

  Enalapril maleate oral solution 1 mg/mL AEMPS

  Reference monograph · Local adoption

• CGR-ES-010

  Amlodipine 0.5 mg/mL oral solution

  Reference monograph · Local adoption

• CGR-ES-011

  Hydrocortisone oral suspension 1 mg/mL AEMPS

  Reference monograph · Local adoption

• CGR-ES-012

  Gabapentin oral solution 50 mg/mL AEMPS

  Reference monograph · Local adoption

• CGR-ES-013

  Sodium citrate/citric acid oral solution AEMPS

  Reference monograph · Local adoption

• CGR-ES-014

  Artificial saliva AEMPS

  Reference monograph · Local adoption

• CGR-BP-043

  Compound Glucose Sodium Chloride and Sodium Citrate Oral Solution

  Reference monograph · Local adoption

• CGR-BE-036

  Aciclovir Oral Suspension 400 mg/5 mL

  Reference monograph · Local adoption

• CGR-BE-037

  Metronidazole Benzoate Suspension 200 mg/5 mL as Metronidazole

  Reference monograph · Local adoption

• CGR-ES-022

  Simple Syrup 84% w/v EX022

  Reference monograph · Local adoption

• CGR-ES-027

  Viscous Lidocaine Hydrochloride 0.5% w/w

  Reference monograph · Local adoption

• CGR-ES-028

  Weak Lugol Solution AEMPS 2025

  Reference monograph · Local adoption

• CGR-ES-029

  Clonidine Hydrochloride Oral Solution 20 micrograms/mL

  Reference monograph · Local adoption

• CGR-ES-030

  Isoniazid Oral Solution 50 mg/mL

  Reference monograph · Local adoption

• CGR-ES-031

  Ethambutol Hydrochloride Oral Solution 50 mg/mL

  Reference monograph · Local adoption

• CGR-ES-032

  Pyridoxine Hydrochloride Oral Solution 25 mg/mL

  Reference monograph · Local adoption

• CGR-ES-033

  Dexamethasone Oral Solution 1 mg/mL

  Reference monograph · Local adoption

• CGR-ES-034

  Hydralazine Hydrochloride Oral Solution 10 mg/mL

  Reference monograph · Local adoption

• CGR-ES-035

  Folic Acid Oral Solution 1 mg/mL

  Reference monograph · Local adoption

• CGR-ES-036

  Thiamine Hydrochloride Oral Solution 100 mg/mL

  Reference monograph · Local adoption

• CGR-ES-037

  Riboflavin Oral Solution 25 mg/mL

  Reference monograph · Local adoption

• CGR-US-001

  Acetazolamide 25 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-US-002

  Allopurinol 20 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-US-003

  Amiodarone 5 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-US-004

  Atenolol 2 mg/mL oral solution

  Reference monograph · Local adoption

• CGR-US-005

  Bethanechol 5 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-US-006

  Carvedilol 0.5 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-US-007

  Celecoxib 10 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-US-008

  Cinacalcet 5 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-US-009

  Lamotrigine 1 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-US-010

  Nifedipine 4 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-US-011

  Quinidine sulfate 10 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-US-012

  Rifabutin 20 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-US-013

  Tinidazole 66.7 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-US-014

  Verapamil 50 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-CA-001

  Baclofen 10 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-CA-002

  Clobazam 1 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-CA-003

  Diazoxide 10 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-CA-004

  Domperidone 1 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-CA-005

  Glycopyrrolate 0.5 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-CA-006

  Lisinopril 1 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-CA-007

  Prednisone 5 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-NZ-001

  Melatonin 1 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-NZ-002

  Carvedilol 1 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-NZ-003

  Sotalol hydrochloride 5 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-NZ-004

  Terbinafine 25 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-NZ-005

  Dipyridamole 10 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-NZ-006

  Flecainide acetate 20 mg/mL oral suspension

  Reference monograph · Local adoption

• CGR-NZ-007

  Phenobarbital sodium 10 mg/mL oral solution

  Reference monograph · Local adoption

• CGR-BR-011

  Sodium fluoride 0.05% w/v mouth rinse

  Reference monograph · Local adoption

• CGR-BR-012

  Chlorhexidine digluconate 0.1% w/v mouth rinse

  Reference monograph · Local adoption

• CGR-BR-013

  Aluminium hydroxide 6% w/v suspension

  Final reference document

• CGR-BR-014

  Aluminium hydroxide 6% and magnesium hydroxide 4% w/v suspension

  Final reference document

• CGR-BR-015

  Lidocaine hydrochloride 2% w/v oromucosal topical solution

  Reference monograph · Local adoption

• CGR-BR-016

  Simple syrup 85% w/v — FNFB

  Fresh intermediate · Same operation

• CGR-FR-030

  Aprepitant 20 mg/mL from 80 mg capsules

  Reference monograph · Local adoption

• CGR-FR-032

  Flucytosine 50 mg/mL oral suspension

  Specialist setting only

• CGR-ES-063

  Thymol water 0.1% PO008

  Reference monograph · Local adoption